Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Recurrent
- Interventions
- Registration Number
- NCT05815160
- Lead Sponsor
- Debiopharm International SA
- Brief Summary
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended dose and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide.
The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the recommended dose when administered in combination with carboplatin and etoposide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
-
Histologically or cytologically confirmed SCLC
-
Tumor that is not bleeding
-
Prior platinum-based chemotherapy (carboplatin and/or cisplatin)
- Part 1 (dose escalation): Recurrence or progression after a minimum of 45 days since the last dose of prior standard platinum-based therapy
- Part 2 (expansion): Recurrence or progression after a minimum of 90 days since the last dose of prior standard platinum-based therapy
-
Measurable disease per RECIST 1.1
-
Willingness and ability to undergo tumor biopsy unless an archived tumor sample is available
-
ECOG performance status of 0-1
-
Life expectancy of at least 3 months in the best judgment of the Investigator
-
Adequate bone marrow, hepatic and renal function, adequate coagulation status
-
Willingness and ability to comply with scheduled visits, study treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria
- Use of an investigational agent or medical device within 28 days prior to first dose of study treatment.
- History of other malignancies requiring active treatment in the last 2 years prior to first dose of study treatment, except for superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent.
- History of myocardial infarction or stroke in the last 6 months prior to first dose of study treatment, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, known family history of sudden death from cardiac-related causes before the age of 50, or any cardiotoxicity experienced after previous chemotherapy.
- Left ventricular ejection fraction (LVEF) below 55%.
- QTcF >450 ms, history of congenital long QT syndrome, or clinically significant conduction abnormality, or any conduction abnormality that may increase the risk of TdP.
- Clinically significant gastrointestinal abnormality that could affect the absorption of orally administered drugs
- Major surgery ≤4 weeks prior to first dose of study treatment or incomplete recovery from the surgical procedure at the time of the first dose of study treatment.
- Radiographic findings showing tumor involvement with large blood vessels or poor demarcation from them with increased risk for bleeding.
- Radiographic findings of Interstitial lung disease (ILD) that are considered clinically significant.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Any infection requiring the systemic use of an antibiotic or antiviral agent.
- Known Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Human Immunodeficiency Virus (HIV) infection. Participants with past infections that have been cured may be enrolled.
- Immunization with live or live-attenuated vaccine within 28 days prior to first dose of study treatment.
- Inability or unwillingness to swallow oral medications.
- Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to first dose of study treatment. Palliative radiation is allowed up to 1 week prior to study treatment start.
- Unresolved AEs or toxicities due to previous treatments >Grade 1. Note: Participants with ≤Grade 2 alopecia or endocrinopathies controlled by replacement therapy are exceptions and may qualify for the study.
- Hypersensitivity to Debio 0123, etoposide or carboplatin, or any of the excipients found in the formulations for Debio 0123, etoposide, or carboplatin. If a prior hypersensitivity to carboplatin has been observed but a successful desensitization was performed for the participant, he or she may be eligible for the study.
- Prior exposure to any WEE1 inhibitor
Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin Debio 0123 Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study. Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin Debio 0123 Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study. Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin Carboplatin Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study. Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin Etoposide Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study. Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin Carboplatin Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study. Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin Etoposide Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
- Primary Outcome Measures
Name Time Method Parts 1 and 2: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) Approximately up to 44 months Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) Cycle 1 (Cycle=21 days) Parts 1 and 2: Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Baseline up to approximately 44 months Parts 1 and 2: Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram Parameters Approximately up to 44 months
- Secondary Outcome Measures
Name Time Method Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Debio 0123 and its Metabolite For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population Pharmacokinetic (PK) model using the sparse samples collected Part 1: Area Under the Concentration Curve up to Infinity (AUCinf) of Debio 0123 and its Metabolite Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days) Part 1: Time to Maximum Plasma Concentration (tmax) of Debio 0123 and its Metabolite Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days) Part 1: Apparent Terminal Half-life (t1/2) of Debio 0123 and its Metabolite Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days) Part 1: Area Under the Concentration Curve Over 24 hours (AUC24h) of Etoposide Multiple timepoints post dose from Day 1 to Day 5 of Cycle 1 (Cycle=21 days) Parts 1 and 2: Percentage of Participants With Objective Response (OR) Assessed as per RECIST 1.1 Criteria Up to end of study (approximately 44 months) Parts 1 and 2: Trough Concentration (Ctrough) of Debio 0123 and its Metabolite For Part 1: Predose from Day 2 to Day 11 of Cycle 1; For Part 2: Predose from Day 3 to Day 10 of Cycle 1 and only Day 8 of subsequent cycles (Cycle=21 days) Part 1: Apparent Volume of Distribution (Vd/F) of Debio 0123 Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days) Parts 1 and 2: Area Under the Concentration Curve Over 24 hours (AUC24h) of Debio 0123 and its Metabolite For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population PK model using the sparse samples collected Part 1: Area Under the Concentration Curve up to the Last Measurable Concentration (AUClast) of Debio 0123 and its Metabolite Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days) Part 1: Maximum Plasma Concentration (Cmax) of Etoposide Multiple timepoints from administration to post dose from Day 1 to Day 3 of Cycle 1 (Cycle=21 days)] Parts 1 and 2: Percentage of Participants With Disease Control (DC) Assessed as per RECIST 1.1 Criteria From the start of study treatment until disease progression or end of study (up to approximately 44 months) Part 1: Apparent Clearance (CL/F) of Debio 0123 Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days) Parts 1 and 2: Percentage of Participants With Best Overall Response (BOR) Assessed as per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria From the start of study treatment until disease progression or end of study (up to approximately 44 months) Parts 1 and 2: Progression Free Survival (PFS) Assessed as per RECIST 1.1 Criteria From the start of study treatment until disease progression or death or end of study (up to approximately 44 months) Part 1: Trough Concentration (Ctrough) of Etoposide Predose from Day 2 to Day 5 of Cycle 1 (Cycle=21 days) Part 1: Maximum Plasma Concentration (Cmax) of Carboplatin Multiple timepoints from administration up to 6 hours post dose on Day 1 of Cycle 1 (Cycle=21 days) Parts 1 and 2: Duration of Response (DOR) Assessed as per RECIST 1.1 Criteria Up to disease progression or end of study (approximately 44 months) Part 2: Overall Survival From the start of study treatment until death from any cause or end of study (up to approximately 44 months
Trial Locations
- Locations (14)
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Roswell Park Comprehensive Cancer Center
🇺🇸Buffalo, New York, United States
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic Barcelona
🇪🇸Barcelona, Spain
Institut Catala D'Oncologia - Badalona
🇪🇸Barcelona, Spain
Hospital Universitario de A Coruna
🇪🇸Coruña, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)
🇪🇸Madrid, Spain
NEXT Oncology Madrid
🇪🇸Madrid, Spain
Hospital Quironsalud Malaga
🇪🇸Málaga, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain